vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and ENTEGRIS INC (ENTG). Click either name above to swap in a different company.
Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $823.9M, roughly 1.2× ENTEGRIS INC). ENTEGRIS INC runs the higher net margin — 6.0% vs 0.7%, a 5.3% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -3.1%). ENTEGRIS INC produced more free cash flow last quarter ($134.0M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 3.4%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
Entegris, Inc. is a supplier of materials for the semiconductor and other high-tech industries. Entegris has approximately 8,000 employees throughout its global operations. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. The company’s corporate headquarters are in Billerica, Massachusetts.
ASTH vs ENTG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $823.9M |
| Net Profit | $6.6M | $49.4M |
| Gross Margin | — | 43.8% |
| Operating Margin | 1.9% | 12.7% |
| Net Margin | 0.7% | 6.0% |
| Revenue YoY | 42.9% | -3.1% |
| Net Profit YoY | 184.4% | -51.7% |
| EPS (diluted) | $0.12 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | $823.9M | ||
| Q3 25 | $956.0M | $807.1M | ||
| Q2 25 | $654.8M | $792.4M | ||
| Q1 25 | $620.4M | $773.2M | ||
| Q4 24 | $665.2M | $849.8M | ||
| Q3 24 | $478.7M | $807.7M | ||
| Q2 24 | $486.3M | $812.7M | ||
| Q1 24 | $404.4M | $771.0M |
| Q4 25 | $6.6M | $49.4M | ||
| Q3 25 | $373.0K | $70.5M | ||
| Q2 25 | $9.4M | $52.8M | ||
| Q1 25 | $6.7M | $62.9M | ||
| Q4 24 | $-7.8M | $102.2M | ||
| Q3 24 | $16.1M | $77.6M | ||
| Q2 24 | $19.2M | $67.7M | ||
| Q1 24 | $14.8M | $45.3M |
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 43.5% | ||
| Q2 25 | — | 44.4% | ||
| Q1 25 | — | 46.1% | ||
| Q4 24 | — | 45.6% | ||
| Q3 24 | — | 46.0% | ||
| Q2 24 | — | 46.2% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | 1.9% | 12.7% | ||
| Q3 25 | 2.0% | 15.2% | ||
| Q2 25 | 3.1% | 13.4% | ||
| Q1 25 | 3.3% | 15.8% | ||
| Q4 24 | 0.1% | 17.6% | ||
| Q3 24 | 5.9% | 16.9% | ||
| Q2 24 | 6.2% | 16.0% | ||
| Q1 24 | 7.5% | 15.3% |
| Q4 25 | 0.7% | 6.0% | ||
| Q3 25 | 0.0% | 8.7% | ||
| Q2 25 | 1.4% | 6.7% | ||
| Q1 25 | 1.1% | 8.1% | ||
| Q4 24 | -1.2% | 12.0% | ||
| Q3 24 | 3.4% | 9.6% | ||
| Q2 24 | 3.9% | 8.3% | ||
| Q1 24 | 3.7% | 5.9% |
| Q4 25 | $0.12 | $0.33 | ||
| Q3 25 | $0.01 | $0.46 | ||
| Q2 25 | $0.19 | $0.35 | ||
| Q1 25 | $0.14 | $0.41 | ||
| Q4 24 | $-0.14 | $0.67 | ||
| Q3 24 | $0.33 | $0.51 | ||
| Q2 24 | $0.40 | $0.45 | ||
| Q1 24 | $0.31 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $360.4M |
| Total DebtLower is stronger | — | $3.7B |
| Stockholders' EquityBook value | $779.3M | $4.0B |
| Total Assets | $2.2B | $8.4B |
| Debt / EquityLower = less leverage | — | 0.94× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | $360.4M | ||
| Q3 25 | $463.4M | $399.8M | ||
| Q2 25 | $342.1M | $376.8M | ||
| Q1 25 | $260.9M | $340.9M | ||
| Q4 24 | $290.8M | $329.2M | ||
| Q3 24 | $350.3M | $432.1M | ||
| Q2 24 | $327.7M | $320.0M | ||
| Q1 24 | $337.3M | $340.7M |
| Q4 25 | — | $3.7B | ||
| Q3 25 | — | $3.8B | ||
| Q2 25 | — | $4.0B | ||
| Q1 25 | — | $4.0B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | — | $4.1B | ||
| Q2 24 | — | $4.1B | ||
| Q1 24 | — | $4.2B |
| Q4 25 | $779.3M | $4.0B | ||
| Q3 25 | $775.5M | $3.9B | ||
| Q2 25 | $765.5M | $3.8B | ||
| Q1 25 | $745.4M | $3.7B | ||
| Q4 24 | $712.7M | $3.7B | ||
| Q3 24 | $704.6M | $3.6B | ||
| Q2 24 | $678.9M | $3.5B | ||
| Q1 24 | $653.5M | $3.4B |
| Q4 25 | $2.2B | $8.4B | ||
| Q3 25 | $2.2B | $8.4B | ||
| Q2 25 | $1.4B | $8.4B | ||
| Q1 25 | $1.3B | $8.4B | ||
| Q4 24 | $1.4B | $8.4B | ||
| Q3 24 | $1.3B | $8.5B | ||
| Q2 24 | $1.3B | $8.3B | ||
| Q1 24 | $1.2B | $8.4B |
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | 0.99× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 1.06× | ||
| Q4 24 | — | 1.08× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.18× | ||
| Q1 24 | — | 1.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $192.0M |
| Free Cash FlowOCF − Capex | $-6.0M | $134.0M |
| FCF MarginFCF / Revenue | -0.6% | 16.3% |
| Capex IntensityCapex / Revenue | 0.3% | 7.0% |
| Cash ConversionOCF / Net Profit | -0.44× | 3.89× |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $396.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $192.0M | ||
| Q3 25 | $10.0M | $249.5M | ||
| Q2 25 | $90.9M | $113.5M | ||
| Q1 25 | $16.6M | $140.4M | ||
| Q4 24 | $-10.9M | $176.1M | ||
| Q3 24 | $34.0M | $197.2M | ||
| Q2 24 | $23.2M | $111.2M | ||
| Q1 24 | $6.0M | $147.2M |
| Q4 25 | $-6.0M | $134.0M | ||
| Q3 25 | $7.4M | $182.8M | ||
| Q2 25 | $89.5M | $47.0M | ||
| Q1 25 | $13.6M | $32.4M | ||
| Q4 24 | $-13.5M | $68.6M | ||
| Q3 24 | $31.7M | $115.0M | ||
| Q2 24 | $20.4M | $51.9M | ||
| Q1 24 | $5.6M | $80.6M |
| Q4 25 | -0.6% | 16.3% | ||
| Q3 25 | 0.8% | 22.6% | ||
| Q2 25 | 13.7% | 5.9% | ||
| Q1 25 | 2.2% | 4.2% | ||
| Q4 24 | -2.0% | 8.1% | ||
| Q3 24 | 6.6% | 14.2% | ||
| Q2 24 | 4.2% | 6.4% | ||
| Q1 24 | 1.4% | 10.4% |
| Q4 25 | 0.3% | 7.0% | ||
| Q3 25 | 0.3% | 8.3% | ||
| Q2 25 | 0.2% | 8.4% | ||
| Q1 25 | 0.5% | 14.0% | ||
| Q4 24 | 0.4% | 12.7% | ||
| Q3 24 | 0.5% | 10.2% | ||
| Q2 24 | 0.6% | 7.3% | ||
| Q1 24 | 0.1% | 8.6% |
| Q4 25 | -0.44× | 3.89× | ||
| Q3 25 | 26.69× | 3.54× | ||
| Q2 25 | 9.65× | 2.15× | ||
| Q1 25 | 2.48× | 2.23× | ||
| Q4 24 | — | 1.72× | ||
| Q3 24 | 2.11× | 2.54× | ||
| Q2 24 | 1.21× | 1.64× | ||
| Q1 24 | 0.40× | 3.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
